AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLIVER Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

The evolution of available pharmacological treatments for variceal bleeding secondary to portal hypertension: A scope review

Eduarda Raísa Cosera, Raphael Bernardo Netoa( ), Izabel Cristina Meister Martins Coelhoa, Norma Possa Marronib, Claudio Augusto Marronib, Camila Moraes Marquesa
Faculdades Pequeno Príncipe, Brazil
Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
Show Author Information

Abstract

Variceal bleeding is one of the main complications of portal hypertension and it presents with 30 to 50% mortality in hospitalized patients. During the period between 1990 to 2017, more than 1.32 million deaths in the world were related to cirrhosis what makes necessary to map available treatments to variceal bleeding secondary to portal hypertension and to analyze the results of the described treatments. The method selected to this study is a scoping review based on the methodology proposed by the Joanna Briggs Institute (JBI) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews Checklist (PRISMA-SCr) guidelines. The guiding question was defined as: "What treatments are available for variceal bleeding secondary to portal hypertension?". Based on these, 2870 articles were identified in the databases, 2446 were screened and 562 were selected for analysis by title and abstract. The texts analyzed in full totaled 110, of which 36 articles published between 2001 and 2020 were selected, with quantitative approaches, case reviews, literature reviews, meta-analyses, and guidelines. It is concluded that beta-blockers are the drugs of choice for primary prophylaxis of variceal bleeding. As for secondary prophylaxis, there is an association of these with nitrates and endoscopic ligation. With regard to acute bleeding, the use of vasoactive drugs is chosen, especially terlipressin. Finally, it is important to emphasize that there is a shortage of clinical studies and a need for investment in new therapies.

Keywords

Clinical treatmentPortal hypertensionpharmacology and variceal bleeding

References

[1]
Martinelli ALC. Hipertensão portal. Medicina (Ribeirão Preto) 2004 Dec 30;37(3/4): 253–61 (In Portuguese), https://doi.org/10.11606/issn.2176-7262.v37i3/4p253-261.
Crossref
[2]

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383(9930):1749–61. https://doi.org/10.1016/S0140-6736(14)60121-5.
Crossref Google Scholar
[3]
Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7: F1000. https://doi.org/10.12688/f1000research.13943.1. Faculty Rev-533. Published 2018 May 2.
Crossref
[4]

Perloff JK. Human dissection and the science and art of Leonardo da Vinci. Am J Cardiol 2013;111(5):775–7. https://doi.org/10.1016/j.amjcard.2012.12.031.
Crossref Google Scholar
[5]

Dzeletovic I, Baron TH. History of portal hypertension and endoscopic treatment of esophageal varices. Gastrointest Endosc 2012;75(6):1244–9. https://doi.org/10.1016/j.gie.2012.02.052.
Crossref Google Scholar
[6]
Chen Y, Qiu H, Zhang X. Transjugular intrahepatic portal shunt in the treatment of portal hypertension due to cirrhosis: single center experience. BMC Surg 2019;19(1):191. Published 2019 Dec 12, https://doi.org/10.1186/s12893-019-0659-5.
Crossref
[7]

Gunarathne LS, Rajapaksha H, Shackel N, et al. CB Herath Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020;26(40):6111–40. https://doi.org/10.3748/wjg.v26.i40.6111.
Crossref Google Scholar
[8]

Lamb L, Baldini Soares C. Scope review: potentialities for the synthesis of methodologies used in qualitative primary research. BIS. Bull Inst Health 2020;20(2):37–43. Retrieved from: https://periodicos.saude.sp.gov.br/bis/article/view/34471.
Crossref Google Scholar
[9]
Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med 2017;15(1):200. Published 2017 Nov 10, https://doi.org/10.1186/s12916-017-0966-6.
Crossref
[10]

Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48(Suppl 1):S68–92. https://doi.org/10.1016/j.jhep.2008.01.021.
Crossref Google Scholar
[11]
Nevens F. Prophylaxis of first variceal bleeding. Acta Gastro-Enterol Belg 2004;67(1):50–3 [cited 2023 Jan 25], Available from: https://europepmc.org/article/med/15149087.
[12]

Schepke M, Kleber G, Nürnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40(1):65–72. https://doi.org/10.1002/hep.20284.
Crossref Google Scholar
[13]

Arab JP, Shah VH. Statins and portal hypertension: A tale of two models. Hepatology 2016;63(6):2044–7. https://doi.org/10.1002/hep.28567.
Crossref Google Scholar
[14]

Tursi T. Use of ß-blocker therapy to prevent primary bleeding of esophageal varices. J Am Acad Nurse Pract 2010;22(12):640–7. https://doi.org/10.1111/j.1745-7599.2010.00567.x.
Crossref Google Scholar
[15]

Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol 2012;18(11):1166–75. https://doi.org/10.3748/wjg.v18.i11.1166.
Crossref Google Scholar
[16]

Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension–primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008;28(2):178–86. https://doi.org/10.1111/j.1365-2036.2008.03729.x.
Crossref Google Scholar
[17]

Biecker E. Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol 2013;19(31):5035–50. https://doi.org/10.3748/wjg.v19.i31.5035.
Crossref Google Scholar
[18]

Garbuzenko DV. Current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding. Curr Med Res Opin 2016;32(3):467–75. https://doi.org/10.1185/03007995.2015.1124846.
Crossref Google Scholar
[19]

Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;(1):CD002147. https://doi.org/10.1002/14651858.CD002147.
Crossref Google Scholar
[20]

Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25(11):1105–40. https://doi.org/10.1007/s12325-008-0118-7.
Crossref Google Scholar
[21]

Wilbur K, Sidhu K. Beta blocker prophylaxis for patients with variceal hemorrhage. J Clin Gastroenterol 2005;39(5):435–40. https://doi.org/10.1097/01.mcg.0000159222.16032.98.
Crossref Google Scholar
[22]

Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005;128(4):870–81. https://doi.org/10.1053/j.gastro.2005.01.047.
Crossref Google Scholar
[23]

Abraldes JG, Angermayr B, Bosch J. The management of portal hypertension. Clin Liver Dis 2005;9(4):685–ⅶ. https://doi.org/10.1016/j.cld.2005.08.001.
Crossref Google Scholar
[24]

Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013;62(11):1634–41. https://doi.org/10.1136/gutjnl-2012-304038.
Crossref Google Scholar
[25]

Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl 2017;23(8):1058–69. https://doi.org/10.1002/lt.24794.
Crossref Google Scholar
[26]

Villanueva C, Miñana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345(9):647–55. https://doi.org/10.1056/NEJMoa003223.
Crossref Google Scholar
[27]

Ravipati M, Katragadda S, Swaminathan PD, Molnar J, Zarling E. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointest Endosc 2009;70(4):658–664.e5. https://doi.org/10.1016/j.gie.2009.02.029.
Crossref Google Scholar
[28]

Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123(4):1013–9. https://doi.org/10.1053/gast.2002.35955.
Crossref Google Scholar
[29]

Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology 2017;66(4):1219–31. https://doi.org/10.1002/hep.29267.
Crossref Google Scholar
[30]

Fallowfield JA, Iredale JP. Targeted treatments for cirrhosis. Expert Opin Ther Targets 2004 Oct;8(5):423–35. https://doi.org/10.1517/14728222.8.5.423.
Crossref Google Scholar
[31]

Chernykh ER, Starostina NM, Paltsev AI, et al. Autologous bone marrow cells in the treatment of cirrhosis of the liver. Bull Exp Biol Med 2007;144(4):640–5. https://doi.org/10.1007/s10517-007-0393-3.
Crossref Google Scholar
[32]

Baldassarre M, Giannone FA, Napoli L, et al. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int 2013;33(9):1298–308. https://doi.org/10.1111/liv.12263.
Crossref Google Scholar
[33]

Mejias M, Coch L, Berzigotti A, et al. Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut 2015;64(4):657–66. https://doi.org/10.1136/gutjnl-2014-307138.
Crossref Google Scholar
[34]

Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut 2020;69(5):953–62. https://doi.org/10.1136/gutjnl-2019-318237.
Crossref Google Scholar
iLIVER
Volume 2 Issue 3,
September 2023
Pages 170-176
DOI: 10.1016/j.iliver.2023.08.005
Cite this article:
Coser ER, Neto RB, Coelho ICMM, et al. The evolution of available pharmacological treatments for variceal bleeding secondary to portal hypertension: A scope review. iLIVER, 2023, 2(3): 170-176. https://doi.org/10.1016/j.iliver.2023.08.005

318

Views

1

Crossref

Altmetrics
Received: 30 May 2023
Revised: 21 August 2023
Accepted: 23 August 2023
Published: 01 September 2023
© 2023 The Authors. Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return